Extended Data Fig. 4: Treatment with senolytics and dietary metabolic abnormalities.
a, Experimental protocol. b, Body weight (BW) and food intake of mice treated with vehicle (Cont), dasatinib and quercetin (D + Q), Navitoclax (Nav), or Gpnmb vaccine (Gpnmb vac) (body weight n = 8, 8, 7, 8, food intake 4, 4, 4, 5). c, Energy expenditure (n = 7, 8, 8, 4). d, Luciferase activity. e, Relative luciferase activity (n = 3, 5, 5, and 3). f, Serum titer of anti-Gpnmb antibody. (n = 5, 5 for 0, 8, 12, 16 weeks, n = 3, 3 for 20 weeks). g, Assay of SA-beta-gal (n = 11, 10, 12 and 6 for 16 weeks, and n = 8, 8, 7 and 10 for 24 weeks). h, Relative expression of Cdkn2a (n = 4, 5, 5, and 3 for 16 weeks and n = 7, 8, 7, and 7 for 24 weeks). i, Glucose tolerance test (GTT, left) and insulin tolerance test (ITT, right) (n = 6, 8, 7, and 7). Changes from basal glucose levels are shown in the ITT graph. j, White blood cell and platelet counts, and bleeding time (n = 3, 4, 4, and 4 for white cell counts, n = 3, 4, 4, and 4 for platelet counts, and n = 5, 3, 3, and 3 for bleeding time). The data were analyzed by repeated measures analysis followed by one-way ANOVA followed by Tukey’s multiple comparison test (b, c, g, and j), by the 2-tailed Student’s t-test (h), or by univariate analysis of variance or repeated measures analysis followed by Tukey’s multiple comparison test (f and i). *P < 0.05, **P < 0.01, NS (not significant). In Extended Data Fig. 4i, *P = 0.024, **P < 0.001 Cont vs. Gpnmb vac, $P = 0.018 Cont vs. D + Q, ##P = 0.007 Cont vs. Nav. The data are shown as box and whisker plots that display the range of the data (whiskers), the 25th and 75th percentiles (box), and the median (solid line) (b, c, g, h, and j) or the mean ± SEM with plots of all individual data (h and j).
